Terms: = Prostate cancer AND TG, Thyroglobulin AND Prognosis
12 results:
1. Factors influencing blood tumor marker concentrations in the absence of neoplasia.
Trapé J; Fernández-Galán E; Auge JM; Carbonell-Prat M; Filella X; Miró-Cañís S; González-Fernández C;
Tumour Biol; 2024; 46(s1):S35-S63. PubMed ID: 38517826
[TBL] [Abstract] [Full Text] [Related]
2. Untargeted lipidomics reveal association of elevated plasma C18 ceramide levels with reduced survival in metastatic castration-resistant prostate cancer patients.
Cattrini C; Manfredi M; Barboro P; Ghirimoldi M; Mennitto A; Martini V; Battioni A; Le Van M; Gobbato S; Branni C; Ayed RB; Pinato DJ; Catalano F; Zanardi E; Boccardo F; Gennari A
Sci Rep; 2023 Oct; 13(1):17791. PubMed ID: 37853018
[TBL] [Abstract] [Full Text] [Related]
3. The prognosis of lipid reprogramming with the HMG-CoA reductase inhibitor, rosuvastatin, in castrated Egyptian prostate cancer patients: Randomized trial.
Karkeet RM; Zekri AN; Sayed-Ahmed MM; Sherif GM; Salem SE; Abdelbary A; Fouad MA; Saad SY
PLoS One; 2022; 17(12):e0278282. PubMed ID: 36480560
[TBL] [Abstract] [Full Text] [Related]
4. Identification of microenvironment related potential biomarkers of biochemical recurrence at 3 years after prostatectomy in prostate adenocarcinoma.
Sun X; Wang L; Li H; Jin C; Yu Y; Hou L; Liu X; Yu Y; Yan R; Xue F
Aging (Albany NY); 2021 Jun; 13(12):16024-16042. PubMed ID: 34133324
[TBL] [Abstract] [Full Text] [Related]
5. PET/CT in the management of differentiated thyroid cancer.
Zampella E; Klain M; Pace L; Cuocolo A
Diagn Interv Imaging; 2021 Sep; 102(9):515-523. PubMed ID: 33926848
[TBL] [Abstract] [Full Text] [Related]
6. ACSS3 represses prostate cancer progression through downregulating lipid droplet-associated protein PLIN3.
Zhou L; Song Z; Hu J; Liu L; Hou Y; Zhang X; Yang X; Chen K
Theranostics; 2021; 11(2):841-860. PubMed ID: 33391508
[TBL] [Abstract] [Full Text] [Related]
7. Discovering novel driver mutations from pan-cancer analysis of mutational and gene expression profiles.
Tegally H; Kensler KH; Mungloo-Dilmohamud Z; Ghoorah AW; Rebbeck TR; Baichoo S
PLoS One; 2020; 15(11):e0242780. PubMed ID: 33232371
[TBL] [Abstract] [Full Text] [Related]
8. BRF1 accelerates prostate tumourigenesis and perturbs immune infiltration.
Loveridge CJ; Slater S; Campbell KJ; Nam NA; Knight J; Ahmad I; Hedley A; Lilla S; Repiscak P; Patel R; Salji M; Fleming J; Mitchell L; Nixon C; Strathdee D; Neilson M; Ntala C; Bryson S; Zanivan S; Edwards J; Robson CN; Goodyear CS; Blyth K; Leung HY
Oncogene; 2020 Feb; 39(8):1797-1806. PubMed ID: 31740786
[TBL] [Abstract] [Full Text] [Related]
9. Oncocytic poorly differentiated (insular) thyroid carcinoma mimicking metastatic adenocarcinoma. A case report and review of the literature.
Laforga JB; Cortés VA
Diagn Cytopathol; 2019 Jun; 47(6):584-588. PubMed ID: 30637975
[TBL] [Abstract] [Full Text] [Related]
10. Association of endothelin-1 gene single-nucleotide polymorphisms and haplotypes with risk of hormone refractory prostate cancer.
Xu D; Wang X; Lou Y
Pharmazie; 2017 Feb; 72(2):103-106. PubMed ID: 29441862
[TBL] [Abstract] [Full Text] [Related]
11. Transcriptome Analysis of WHV/c-myc Transgenic Mice Implicates Cytochrome P450 Enzyme 17A1 as a Promising Biomarker for Hepatocellular Carcinoma.
Wang F; Huang J; Zhu Z; Ma X; Cao L; Zhang Y; Chen W; Dong Y
Cancer Prev Res (Phila); 2016 Sep; 9(9):739-49. PubMed ID: 27339169
[TBL] [Abstract] [Full Text] [Related]
12. Pediatric population reference value distributions for cancer biomarkers and covariate-stratified reference intervals in the CALIPER cohort.
Bevilacqua V; Chan MK; Chen Y; Armbruster D; Schodin B; Adeli K
Clin Chem; 2014 Dec; 60(12):1532-42. PubMed ID: 25261558
[TBL] [Abstract] [Full Text] [Related]
